Standout Papers
- Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis (2000)
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritis (1995)
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (1999)
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials (1993)
- American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis (2010)
Immediate Impact
2 by Nobel laureates 5 from Science/Nature 188 standout
Citing Papers
Novel treatment strategies in rheumatoid arthritis
2017 Standout
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
2017 Standout
Works of Daniel E. Fürst being referenced
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
2005
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
1995 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Daniel E. Fürst | 12018 | 4902 | 5160 | 252 | 21.5k | |
| John T. Sharp | 19976 | 3075 | 6319 | 212 | 30.1k | |
| Michael H. Weisman | 14535 | 2301 | 4915 | 338 | 21.6k | |
| Larry W. Moreland | 11918 | 2245 | 4910 | 285 | 18.4k | |
| Edward Keystone | 16716 | 3069 | 7726 | 400 | 24.0k | |
| Ben A. C. Dijkmans | 17930 | 2283 | 6033 | 330 | 24.4k | |
| Joel M. Kremer | 14904 | 2305 | 6764 | 323 | 22.7k | |
| Mark C. Genovese | 13775 | 2456 | 6345 | 315 | 22.2k | |
| Vibeke Strand | 14990 | 2523 | 5499 | 514 | 22.2k | |
| Frank C. Arnett | 23969 | 7105 | 5579 | 196 | 37.1k | |
| Daniel E. Furst | 5906 | 6622 | 2264 | 374 | 16.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...